Skip to content
ContentLora

    Tip: press / anywhere to search.

    Explainer

    How FDA drug approval works: from IND to approval

    Before a new drug can be tested in people across the US, its sponsor files an Investigational New Drug (IND) application, which FDA has 30 days to review.[1][2] After Phase 1 to 3 trials, the company files a New Drug Application (NDA) or, for biological products, a Biologics License Application (BLA).[3][4] Under user-fee law, FDA aims to act on most new-drug applications within 10 months of filing, or 6 months under Priority Review.[5][6] Fast Track, Breakthrough Therapy, Accelerated Approval and, since 2025, national priority vouchers can shorten parts of the process.[7][8][9][10]

    Editor reviewedStrict sourcingUpdated Explainer34 claims · 100% primaryHealth and medicine, Science
    Reading level: 1 passage differs; the rest is the same for everyone.

    This explainer describes how the US Food and Drug Administration reviews new medicines. It is not medical advice. Whether a medicine is right for you is a question for a clinician or pharmacist. The page covers drugs and biologics, not medical devices or food.

    A new medicine reaches US patients only after FDA approves a marketing application. Since 1938 every new drug has needed an approved New Drug Application (NDA) before it can be sold in the US.[3] The path to that point runs through animal studies, an Investigational New Drug (IND) application, phased clinical trials and a formal review.

    Step 1: the IND, permission to test in people

    Federal law requires a drug to have an approved marketing application before it is shipped across state lines. A sponsor that wants to send an experimental drug to clinical investigators in several states therefore files an IND to obtain an exemption.[1] The IND must contain animal pharmacology and toxicology data showing whether the product is reasonably safe for first tests in humans, manufacturing information, and detailed clinical protocols with information on the investigators.[11]

    FDA has 30 days to review an original IND. It can let trials begin or place a clinical hold to delay or stop them, though FDA says holds are rare and it more often sends comments to improve the trial.[2] A treatment IND can also be filed for experimental drugs that show promise for serious or immediately life-threatening conditions while final clinical work and FDA review are still under way.[12]

    Step 2: clinical trials in three phases

    FDA describes Phase 1 studies as involving 20 to 100 people over several months to test safety and dosage.[13] Phase 2 involves up to several hundred people and looks at efficacy and side effects.[14] Phase 3 trials enrol 300 to 3,000 people over 1 to 4 years to show whether the product offers a treatment benefit.[15] The clinical trials explainer covers randomisation, blinding and how to read results.

    Step 3: the NDA or BLA review

    A company files an NDA containing everything from preclinical data to Phase 3 results. Once FDA accepts the application as complete, its review team has 6 to 10 months to decide whether to approve.[16] The data gathered under the IND become part of the NDA.[3] FDA uses it to decide whether the drug is safe and effective for its proposed use, whether its benefits outweigh its risks, whether the proposed labeling is appropriate, and whether manufacturing preserves the drug’s quality.[17] Biological products, such as many vaccines and antibodies, go through a Biologics License Application (BLA) instead. If the data and the manufacturing facility meet FDA’s standards, the agency issues a US license.[4]

    FDA can refuse to file an incomplete application. For a complete one, reviewers examine their own sections, inspectors visit clinical study sites, and a senior FDA official makes the decision on the review team’s recommendation.[18] FDA may also ask independent advisory committees for expert advice on scientific, technical and policy questions.[19] Often there are remaining issues, and FDA may ask the developer to answer questions from existing data or to run more studies. Developers who disagree with a decision can appeal formally.[20] When FDA approves a drug, it works with the company on the prescribing information, called labeling, which describes the basis for approval and how best to use the drug.[21]

    PDUFA: user fees and review deadlines

    The Prescription Drug User Fee Act (PDUFA), created by Congress in 1992, lets FDA collect fees from companies that submit certain drug applications. It must be reauthorised every five years, and the current version, PDUFA VII, runs through September 2027.[22] In fiscal year 2027 the fee for an application that needs clinical data is $4,600,753.[23]

    The law also set review goals. In 1992 FDA created a two-tier system of Standard Review and Priority Review.[24] Under PDUFA VII, FDA commits to act on 90% of standard new molecular entity NDAs and original BLAs within 10 months of the 60-day filing date, and on 90% of priority ones within 6 months of that date.[5]

    Ways to speed things up

    FDA has four main tools for promising drugs for serious illnesses. Fast Track and Breakthrough Therapy bring more help from FDA during development. Priority Review shortens the review itself. Accelerated Approval lets a drug be approved early on a marker that is likely to predict benefit, as long as the company later confirms that it works.[7][8][6][9]

    • Priority Review. FDA aims to act within 6 months instead of 10. It goes to drugs that would significantly improve treatment, diagnosis or prevention of serious conditions, and it does not lower the standard of evidence.[6] FDA says within 60 days of receiving an application whether it qualifies.[25]
    • Fast Track. For drugs for serious conditions that fill an unmet need. It brings more frequent meetings and written communication with FDA, and rolling review, in which completed sections of an application can be submitted early.[7] The company must ask for it, and FDA decides within 60 days.[26]
    • Breakthrough Therapy. For drugs where early clinical evidence suggests a substantial improvement over available therapy. It includes all Fast Track features plus intensive guidance from as early as Phase 1.[8]
    • Accelerated Approval. Since 1992, drugs for serious conditions with an unmet need can be approved on a surrogate endpoint.[9] A surrogate is a marker, such as a lab value or an imaging result, that is thought to predict benefit but does not itself measure it.[27] The company must still confirm the benefit, and FDA can withdraw the approval if confirmatory trials fail.[28]

    The designations can stack. The Alzheimer’s drug donanemab had Fast Track, Priority Review and Breakthrough Therapy designations.[29] Lecanemab was granted Accelerated Approval in January 2023 based on its effect on amyloid plaques. FDA converted it to traditional approval in July 2023 after a confirmatory trial verified clinical benefit (see Alzheimer’s disease explained).[30]

    The national priority voucher pilot

    FDA announced the Commissioner’s National Priority Voucher (CNPV) pilot in June 2025. It uses a “tumor board-style” review to speed products that match one of five national priorities: public health crises, breakthrough therapies, large unmet needs, onshoring of manufacturing, and affordability.[10] FDA says CNPV targets a review of 1–2 months, against 6 months or more for its other priority programs, and the vouchers cannot be transferred.[31] FDA also says applications in the program face the same legal requirements for approval as other applications, and the decision stays with the relevant FDA center.[32]

    FDA’s CNPV page records the first vouchers going to nine sponsors on 16 October 2025, the program’s seventh approval on 8 May 2026, and more approvals through 19 October 2026.[33] FDA held a public hearing on the pilot on 4 June 2026.[34]

    For who runs these reviews, see the FDA entity page. For what happens when an approved product has to be pulled from shelves, see the recall explainer.

    Next in the crash course

    Go deeper

    Questions readers ask

    What is an IND?

    An Investigational New Drug application is how a sponsor gets an exemption from the federal rule that a drug needs an approved marketing application before it crosses state lines. It contains animal safety data, manufacturing information and the planned trial protocols, and FDA has 30 days to review it.[1][11][2]

    What is the difference between an NDA and a BLA?

    An NDA is the application to market a new drug in the US, required since 1938. A BLA is the equivalent request for a biological product. If FDA's standards are met, the agency issues a US license.[3][4]

    What are PDUFA review deadlines?

    The Prescription Drug User Fee Act, first passed in 1992, funds FDA reviews through company fees and sets review goals. Under PDUFA VII, FDA aims to act on 90% of standard new molecular entity applications within 10 months of the 60-day filing date, and on priority ones within 6 months.[22][5]

    Does Priority Review mean a lower bar for approval?

    No. Priority Review shortens FDA's goal from 10 months to 6, but FDA says it does not change the scientific or medical standard for approval or the quality of evidence needed.[6]

    What is accelerated approval?

    Since 1992, drugs for serious conditions with an unmet need can be approved on a surrogate endpoint, a marker thought to predict benefit. The company must still confirm the benefit, and FDA can withdraw the approval if confirmatory trials fail.[9][27][28]

    What is a national priority voucher?

    The Commissioner's National Priority Voucher pilot, announced in June 2025, targets a 1–2 month review for products that match national priorities such as unmet needs, onshoring and affordability. FDA says the approval standards stay the same, and the vouchers cannot be transferred.[10][31][32]

    Sources

    · 34 claims from 1 publisher

    Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.

    1. [1]

      Federal law requires a drug to have an approved marketing application before it is shipped across state lines, so a sponsor that wants to send an experimental drug to clinical investigators files an Investigational New Drug (IND) application to obtain an exemption. confirmedas of 2026-11-07

    2. [2]

      FDA has 30 days to review an original IND; it can let trials begin or place a clinical hold to delay or stop them, though FDA says holds are rare and it more often sends comments to improve the trial. confirmedas of 2026-11-07

      • Step 3: Clinical Research · US Food and Drug Administration · Primary source · IND Review and Approval (retrieved 2026-11-07)
      • Step 3: Clinical Research · US Food and Drug Administration · Primary source · IND Review and Approval (retrieved 2026-11-07)
    3. [3]

      Since 1938 every new drug has needed an approved New Drug Application (NDA) before it can be sold in the US, and the animal and human data gathered under the IND become part of the NDA. confirmedas of 2026-11-07

    4. [4]

      Biological products are licensed through a Biologics License Application (BLA), the formal request to introduce a biological product into interstate commerce; if the data and the manufacturing facility meet FDA's standards, the agency issues a US license. confirmedas of 2026-11-07

    5. [5]

      Under PDUFA VII, FDA commits to review and act on 90% of standard new molecular entity NDAs and original BLAs within 10 months of the 60-day filing date, and 90% of priority ones within 6 months of that date. confirmedas of 2026-11-07

    6. [6]

      Priority Review means FDA aims to act on an application within 6 months instead of 10 under standard review; it goes to drugs that would significantly improve the treatment, diagnosis or prevention of serious conditions, and it does not lower the standard of evidence for approval. confirmedas of 2026-11-07

      • Priority Review · US Food and Drug Administration · Primary source (retrieved 2026-11-07)
      • Priority Review · US Food and Drug Administration · Primary source (retrieved 2026-11-07)
      • Priority Review · US Food and Drug Administration · Primary source (retrieved 2026-11-07)
    7. [7]

      Fast Track is meant to speed the development and review of drugs for serious conditions that fill an unmet medical need; it offers more frequent meetings and written communication with FDA and rolling review, in which completed sections of an application can be submitted before the whole application is finished. confirmedas of 2026-11-07

      • Fast Track · US Food and Drug Administration · Primary source (retrieved 2026-11-07)
      • Fast Track · US Food and Drug Administration · Primary source (retrieved 2026-11-07)
      • Fast Track · US Food and Drug Administration · Primary source (retrieved 2026-11-07)
      • Fast Track · US Food and Drug Administration · Primary source (retrieved 2026-11-07)
    8. [8]

      Breakthrough Therapy designation is for drugs for serious conditions where preliminary clinical evidence suggests a substantial improvement over available therapy; it includes all Fast Track features plus intensive FDA guidance from as early as Phase 1, and FDA answers requests within 60 days. confirmedas of 2026-11-07

    9. [9]

      FDA created Accelerated Approval in 1992 so that drugs for serious conditions with an unmet medical need could be approved on the basis of a surrogate endpoint. confirmedas of 2026-11-07

    10. [10]

      FDA announced the Commissioner's National Priority Voucher (CNPV) pilot in June 2025; it uses a "tumor board-style" review to speed products that align with one of five national priorities, which include public health crises, breakthrough therapies, large unmet needs, onshoring of manufacturing and affordability. confirmedas of 2026-11-07

    11. [11]

      An IND must contain animal pharmacology and toxicology data showing whether the product is reasonably safe for first tests in humans, manufacturing information, and detailed clinical protocols with information on the investigators. confirmedas of 2026-11-07

    12. [12]

      A treatment IND can be submitted for experimental drugs that show promise for serious or immediately life-threatening conditions while final clinical work and FDA review are still under way. confirmedas of 2026-11-07

    13. [13]

      FDA describes Phase 1 studies as involving 20 to 100 healthy volunteers or people with the condition for several months, with the purpose of testing safety and dosage; about 70% of drugs move on to the next phase. confirmedas of 2026-11-07

    14. [14]

      FDA describes Phase 2 studies as involving up to several hundred people with the condition for several months to 2 years, to study efficacy and side effects; about 33% of drugs move on to the next phase. confirmedas of 2026-11-07

    15. [15]

      FDA describes Phase 3 studies, sometimes called pivotal studies, as involving 300 to 3,000 people with the condition over 1 to 4 years, designed to show whether a product offers a treatment benefit; about 25-30% of drugs move on to the next phase. confirmedas of 2026-11-07

    16. [16]

      To market a new drug, a developer files a New Drug Application containing everything from preclinical data to Phase 3 results; once FDA accepts the application as complete, its review team has 6 to 10 months to decide whether to approve. confirmedas of 2026-11-07

      • Step 4: FDA Drug Review · US Food and Drug Administration · Primary source · New Drug Application (retrieved 2026-11-07)
      • Step 4: FDA Drug Review · US Food and Drug Administration · Primary source · FDA Review (retrieved 2026-11-07)
    17. [17]

      FDA uses an NDA to decide whether the drug is safe and effective for its proposed use and its benefits outweigh its risks, whether the proposed labeling is appropriate, and whether manufacturing methods and controls preserve the drug's quality. confirmedas of 2026-11-07

    18. [18]

      During an NDA review FDA can refuse to file an incomplete application; for a complete one, reviewers examine their own sections, inspectors visit clinical study sites, and a senior FDA official makes the decision on the review team's recommendation. confirmedas of 2026-11-07

    19. [19]

      FDA uses advisory committees and panels to obtain independent expert advice on scientific, technical and policy matters. confirmedas of 2026-11-07

      • Advisory Committees · US Food and Drug Administration · Primary source (retrieved 2026-11-07)
    20. [20]

      FDA often has remaining issues to resolve before approval and may ask the developer to answer questions from existing data or to run additional studies; developers who disagree with a decision can appeal formally. confirmedas of 2026-11-07

      • Step 4: FDA Drug Review · US Food and Drug Administration · Primary source · FDA Approval (retrieved 2026-11-07)
      • Step 4: FDA Drug Review · US Food and Drug Administration · Primary source · FDA Approval (retrieved 2026-11-07)
    21. [21]

      When FDA finds a drug safe and effective, it works with the applicant on the prescribing information, called labeling, which describes the basis for approval and how best to use the drug. confirmedas of 2026-11-07

      • Step 4: FDA Drug Review · US Food and Drug Administration · Primary source · FDA Approval (retrieved 2026-11-07)
    22. [22]

      The Prescription Drug User Fee Act (PDUFA), created by Congress in 1992, lets FDA collect fees from companies that submit certain drug applications; it must be reauthorised every five years, and the current version, PDUFA VII, runs through September 2027. confirmedas of 2026-11-07

    23. [23]

      FDA's PDUFA fee for an application requiring clinical data is $4,600,753 in fiscal year 2027, down from $4,682,003 in fiscal year 2026. confirmedas of 2026-11-07

    24. [24]

      Under PDUFA in 1992, FDA agreed to review-time goals and created a two-tier system of Standard Review and Priority Review. confirmedas of 2026-11-07

      • Priority Review · US Food and Drug Administration · Primary source (retrieved 2026-11-07)
    25. [25]

      FDA tells an applicant within 60 days of receiving an original NDA, BLA or efficacy supplement whether it has Priority Review. confirmedas of 2026-11-07

      • Priority Review · US Food and Drug Administration · Primary source (retrieved 2026-11-07)
    26. [26]

      The drug company must request Fast Track, and FDA decides on the request within 60 days. confirmedas of 2026-11-07

      • Fast Track · US Food and Drug Administration · Primary source (retrieved 2026-11-07)
      • Fast Track · US Food and Drug Administration · Primary source (retrieved 2026-11-07)
    27. [27]

      A surrogate endpoint is a marker, such as a lab measurement, imaging result or physical sign, that is thought to predict clinical benefit but is not itself a measure of clinical benefit. confirmedas of 2026-11-07

    28. [28]

      After Accelerated Approval the company must still run studies to confirm the clinical benefit, and FDA can withdraw the approval or change the labeled use if those trials fail to verify it. confirmedas of 2026-11-07

    29. [29]

      FDA approved donanemab (Kisunla) for Alzheimer's in July 2024, for people with mild cognitive impairment or mild dementia, the population studied in trials; the application had Fast Track, Priority Review and Breakthrough Therapy designations. confirmedas of 2026-11-07

    30. [30]

      Lecanemab (Leqembi) received Accelerated Approval in January 2023 based on its effect on amyloid plaques, then FDA converted it to traditional approval on 6 July 2023 after a confirmatory trial verified clinical benefit. confirmedas of 2026-11-07

    31. [31]

      FDA says CNPV targets a review of 1–2 months, against 6 months or more for its other priority programs, and that the vouchers cannot be transferred. confirmedas of 2026-11-07

    32. [32]

      FDA says applications in the CNPV program face the same statutory and regulatory requirements for approval as other applications, and the approval decision stays with the relevant FDA center. confirmedas of 2026-11-07

    33. [33]

      FDA's CNPV page lists the first vouchers going to nine sponsors on 16 October 2025, the program's seventh approval on 8 May 2026, and further approvals through 19 October 2026. confirmedas of 2026-11-07

    34. [34]

      FDA held a public hearing on the CNPV pilot on 4 June 2026 to gather feedback. confirmedas of 2026-11-07

    Revision history (1)
    1. Page created.

    Created Nov 7, 2026. Last reviewed by an editor on Nov 8, 2026. Next scheduled review: Mar 31, 2027.

    Cite this page

    "How FDA drug approval works: from IND to approval." ContentLora, updated Nov 7, 2026. https://contentlora.com/explain/how-fda-drug-approval-works

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.